Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$27,000.00

Developing pragmatic clinical trials to improve patient-centered outcomes in hematologic malignancies

EF 2024-25

Résumé
As a hematologist and aspiring clinician-investigator, I will evaluate whether pragmatic trials can address important questions in cancer care delivery and reduce toxicity and burdens of therapy on patients.In the last twenty years many new cancer therapeutics have emerged, but there is limited evidence on how to best utilize them, leading to a large efficacy-effectiveness gap. In response, groups like the Canadian SPOR and Common Sense Oncology are advocating for the generation of more patient-centered evidence to inform medical practice. The REaCT program based out of The Ottawa Hospital has successfully created several trials with precisely this goal in mind, but none of them have included patients with hematologic malignancies.With the support of my supervisors Dr Dean Fergusson and Dr Natasha Kekre, we identified testing an alternative dosing strategy of decitabine-cedazuridine in myelodysplastic syndrome as an attractive opportunity for improving patient outcomes. This is a newly established standard-of-care drug for which indirect evidence exists to support alternate dosing strategies. Initiation of treatment is associated with significant burdens on patients and a high risk of serious infections, so starting the drug at a lower dose may decrease these adverse effects. Because little data exists to to inform the conduct of such a trial, I will first investigate local outcomes with this treatment. I will then use the local expertise of my supervisors and REaCT investigators to integrate pragmatic design elements and conduct a feasibility study of a suitable alternative dosing strategy. If successful, a well-powered trial could then be conducted within MYELO-CAN, a recently created Canadian trial platform in which I am a trainee co-investigator.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530269
Name
Giguère Philippe
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing pragmatic clinical trials to improve patient-centered outcomes in hematologic malignancies
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clinical Trials; Hematologic Malignancies; Patient-Centered Research; Pragmatic Clinical Trials; Systematic Reviews
Abstract
As a hematologist and aspiring clinician-investigator, I will evaluate whether pragmatic trials can address important questions in cancer care delivery and reduce toxicity and burdens of therapy on patients.In the last twenty years many new cancer therapeutics have emerged, but there is limited evidence on how to best utilize them, leading to a large efficacy-effectiveness gap. In response, groups like the Canadian SPOR and Common Sense Oncology are advocating for the generation of more patient-centered evidence to inform medical practice. The REaCT program based out of The Ottawa Hospital has successfully created several trials with precisely this goal in mind, but none of them have included patients with hematologic malignancies.With the support of my supervisors Dr Dean Fergusson and Dr Natasha Kekre, we identified testing an alternative dosing strategy of decitabine-cedazuridine in myelodysplastic syndrome as an attractive opportunity for improving patient outcomes. This is a newly established standard-of-care drug for which indirect evidence exists to support alternate dosing strategies. Initiation of treatment is associated with significant burdens on patients and a high risk of serious infections, so starting the drug at a lower dose may decrease these adverse effects. Because little data exists to to inform the conduct of such a trial, I will first investigate local outcomes with this treatment. I will then use the local expertise of my supervisors and REaCT investigators to integrate pragmatic design elements and conduct a feasibility study of a suitable alternative dosing strategy. If successful, a well-powered trial could then be conducted within MYELO-CAN, a recently created Canadian trial platform in which I am a trainee co-investigator.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Giguère, Philippe
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~